SCHEMBL27188904

SCHEMBL27188904

CCOc1ncncc1CNC(=O)c1cc(F)c(OC(F)F)c(F)c1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ SCN2A Q99250 1/20 0.40
▸ SCN10A Q9Y5Y9 1/20 0.40
▸ LMNA P02545 4/20 0.39
▸ EPHX2 P34913 2/20 0.35
▸ MAPK8 P45983 1/20 0.34
▸ ALDH1A1 P00352 2/20 0.34
▸ MAPK1 P28482 1/20 0.34
▸ PPARD Q03181 1/20 0.33
▸ PPARA Q07869 1/20 0.33
▸ KCNA5 P22460 1/20 0.33
▸ KCNH2 Q12809 1/20 0.33
▸ KCNB1 Q14721 1/20 0.33
▸ NR1H4 Q96RI1 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ DGAT2 Q96PD7 1/20 0.33
▸ DDR1 Q08345 1/20 0.32
▸ ROCK2 O75116 1/20 0.32
▸ HPGD P15428 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27188850 0.91 EPHX2 (0.40) EPHX2ALDH1A1MAPK1PPARDPPARA
SCHEMBL23143274 0.89 SCN2A (0.41) SCN2ASCN10ALMNAEPHX2MAPK8
SCHEMBL29896095 0.89 SCN2A (0.41) SCN2ASCN10ALMNAEPHX2MAPK8
SCHEMBL29896143 0.88 SCN2A (0.42) SCN2ASCN10ALMNAMAPK8ALDH1A1
SCHEMBL27188882 0.88 SCN2A (0.42) SCN2ASCN10ALMNAMAPK8ALDH1A1
SCHEMBL29896117 0.87 PDE4A (0.39) EPHX2DGAT2
SCHEMBL27188836 0.87 PDE4A (0.39) EPHX2DGAT2
SCHEMBL29896133 0.82 SCN2A (0.45) SCN2ASCN10ALMNAEPHX2MAPK8
SCHEMBL27188873 0.82 SCN2A (0.45) SCN2ASCN10ALMNAEPHX2MAPK8
SCHEMBL27188861 0.80 ALDH1A1 (0.40) LMNAALDH1A1PPARDPPARAROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4034257-B1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICALS CO (JP) 2024-05-22 — — EP claimed
EP-4034257-B1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICALS CO (JP) 2024-05-22 — — EP disclosed
US-11952344-B2 Heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2024-04-09 — — US disclosed
US-20220340527-A1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2022-10-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220340527-A1 HETEROCYCLIC COMPOUND AND USE THEREOF GRIN1, GRIN2A, GRIN2B SCN2A 31/4885SCN10A 29/4885LMNA 1986/4885
US-11952344-B2 Heterocyclic compound and use thereof GRIN1, GRIN2A, GRIN2B SCN2A 31/4885SCN10A 29/4885LMNA 1986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback